Vaccination with cancer cells exposed to ICD-inducers (e.g., mitoxantrone20) are expected to successfully prevent tumor engraftment when challenged, by priming an antigen-specific CD8+ T cell response (Supplementary Fig. 4a). Here, CD8A is linked to neoplasm.